IP Library Granted Patent US 12,303,896
Granted Patent B2
US 12,303,896 · App. 17/206,471 · Granted May 20, 2025

Biological fluid filtration system

Inventor: Jayant Parthasarathy (Excelsior, MN)
Assignee: Astrin Biosciences, Inc.
B01L3/502753B01D46/0013B01D46/0028B01D46/2414B01D46/522B01D46/64B01D46/70B01D53/78B01L3/502715B01L2300/0654B01L2300/0681
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,303,896
App. No.
17/206,471
Granted
May 20, 2025
Kind
B2
Abstract

A biological fluid filtration system for scanning a biological fluid so as to filter potentially undesirable constituents from the biological fluid for therapeutic or diagnostic purposes. The biological fluid filtration system generally includes a fluid receiving device adapted to receive a biological fluid. A valve including an inlet, a first outlet, and a second outlet is fluidly connected to the fluid receiving device. The biological fluid within the fluid receiving device is scanned by a scanner to produce scanned data relating to the biological fluid. A control unit in communication with the scanner and the valve receives the scanned data and controls the valve based on the scanned data. The valve is controlled to direct the biological fluid through either the first or second outlet of the valve depending upon the constituents of the biological fluid identified by the control unit.

Claims (24)

1. A method of testing a drug ex vivo on a biological fluid, comprising the steps of: receiving the biological fluid by a fluid filtration device, wherein the fluid filtration device includes an optical scanner comprising a digital holographic microscope, a control unit in communication with the optical scanner, wherein the control unit is configured to receive scanned data from the optical scanner and to compare the scanned data to reference data, wherein the reference data comprise one or more characteristics of a healthy cell; and wherein the control unit is configured to recognize the one or more characteristics of the healthy cell within the scanned data, a first outlet and a second outlet, wherein the fluid filtration device is adapted to receive the biological fluid and generate the scanned data relating to the biological fluid within the fluid receiving device using the optical scanner; separating a first subset of constituents and a second subset of constituents from the biological fluid by the fluid filtration device, wherein the first subset of constituents is determined to include an undesirable constituent using the scanned data; directing the first subset of constituents through the first outlet of the fluid filtration device; directing the second subset of constituents through the second outlet of the fluid filtration device; and testing the drug on the first subset of constituents.

2. The method of claim 1 , further comprising the step of isolating the first subset of constituents ex vivo.

3. The method of claim 1 , further comprising the step of applying genomic profiling to the first subset of constituents.

4. The method of claim 1 , further comprising the step of applying transcriptomic profiling to the first subset of constituents.

5. The method of claim 1 , wherein the undesirable constituent is comprised of an unhealthy cell.

6. The method of claim 5 , wherein the undesirable constituent is comprised of a circulating tumor cell.

7. The method of claim 5 , wherein the undesirable constituent is comprised of a circulating tumor cell cluster.

8. The method of claim 1 , wherein the undesirable constituent is comprised of a pathogen.

9. The method of claim 1 , wherein the second subset of constituents does not include the undesirable constituent.

10. The method of claim 9 , further comprising the step of returning the second subset of constituents to a source of the biological fluid.

11. The method of claim 1 , wherein the drug is comprised of a chemotherapeutic agent.

12. The method of claim 1 , wherein the drug is comprised of an immunotherapy treatment.

13. The method of claim 1 , wherein the biological fluid is comprised of blood.

14. The method of claim 1 , wherein the biological fluid is comprised of a leukapheresis extract.

15. The method of claim 1 , wherein the first outlet of the fluid filtration device is fluidly connected to an isolation channel.

16. The method of claim 15 , wherein the second outlet of the fluid filtration device is fluidly connected to a source of the biological fluid.

17. The method of claim 1 , wherein the fluid filtration device further comprises

a valve comprising an inlet, a first outlet, and a second outlet, wherein the inlet of the valve is fluidly connected to the fluid receiving device, wherein the first outlet of the valve is fluidly connected to the first outlet of the fluid filtration device, and wherein the second outlet of the valve is fluidly connected to the second outlet of the fluid filtration device; and

a control unit in communication with the optical scanner and the valve, wherein the control unit is configured to receive the scanned data from the optical scanner, and wherein the control unit is configured to control the valve based on the scanned data from the optical scanner; wherein the control unit is configured to control the valve to (a) direct the biological fluid including the first subset of constituents through the first outlet if the control unit determines that the scanned data indicates a presence of an undesirable constituent within the biological fluid or (b) direct the biological fluid including the second subset of constituents through the second outlet if the control unit determines that the scanned data does not indicate a presence of an undesirable constituent within the biological fluid.

18. The method of claim 1 , further comprising the step of culturing the first subset of constituents.

19. The method of claim 1 , further comprising the step of performing drug resistance diagnostics on the first subset of constituents.

20. The method of claim 1 , further comprising the step of performing drug sensitivity diagnostics on the first subset of constituents.

21. The method of claim 1 , wherein the optical scanner is configured to scan the biological fluid within the fluid filtration device to produce the scanned data relating to the biological fluid within the fluid filtration device, wherein the scanner comprises a light source and a digital holographic microscope objective.

22. The method of claim 1 , wherein the second subset of constituents comprises healthy cells.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 9, 2025
From: PARTHASARATHY, JAYANT
To: ASTRIN BIOSCIENCES, INC.
Reel/Frame 070788/0429 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 19, 2021
From: PARTHASARATHY, JAYANT, MR.
To: ASTRIN BIOSCIENCES, INC.
Reel/Frame 055665/0686 →
Continuity (3)
Continuation 17162450 · Jan 29, 2021
Provisional Application 62968476 · Jan 31, 2020
Related Publication 20210237074A1 · Aug 5, 2021
References Cited (149)
US 5316725A · Carver, Jr. et al. · 1994 [cited by applicant]
US 5628727A · Hakky et al. · 1997 [cited by applicant]
US 8241238B2 · Hiruma · 2012 [cited by applicant]
US 8548219B2 · Ortyn · 2013 [cited by applicant]
US 9422517B2 · Chen · 2016 [cited by applicant]
US 9458489B2 · Lim · 2016 [cited by applicant]
US 9545471B2 · van Rijn · 2017 [cited by applicant]
US 9808803B2 · Toner · 2017 [cited by applicant]
US 10073024B2 · Nagrath · 2018 [cited by applicant]
US 10147180B2 · Couch et al. · 2018 [cited by applicant]
US 10386384B2 · Hong · 2019 [cited by applicant]
US 10519175B2 · Londesbrough et al. · 2019 [cited by applicant]
US 12162010B2 · Parthasarathy et al. · 2024 [cited by applicant]
US 20020033939A1 · Hansen · 2002 [cited by applicant]
US 20020058332A1 · Quake et al. · 2002 [cited by applicant]
US 20020182738A1 · Connelly et al. · 2002 [cited by applicant]
US 20030198523A1 · Bohm et al. · 2003 [cited by applicant]
US 20040072278A1 · Chou · 2004 [cited by applicant]
US 20040161143A1 · Dietz · 2004 [cited by applicant]
US 20050142570A1 · Parthasarathy et al. · 2005 [cited by applicant]
US 20050221271A1 · Murphy et al. · 2005 [cited by applicant]
US 20050255001A1 · Padmanabhan et al. · 2005 [cited by applicant]
US 20070054350A1 · Walker, Jr. et al. · 2007 [cited by applicant]
US 20070286254A1 · Fon et al. · 2007 [cited by applicant]
US 20080038713A1 · Gao et al. · 2008 [cited by applicant]
US 20080213821A1 · Liu et al. · 2008 [cited by applicant]
US 20080248499A1 · Chiu · 2008 [cited by applicant]
US 20080261295A1 · Bulter et al. · 2008 [cited by applicant]
US 20090198168A1 · Hiruma · 2009 [cited by applicant]
US 20110003325A1 · Durack · 2011 [cited by applicant]
US 20110217729A1 · Hong · 2011 [cited by examiner]
US 20120021453A1 · Patra et al. · 2012 [cited by applicant]
US 20120129190A1 · Chiu et al. · 2012 [cited by applicant]
US 20120264646A1 · Link · 2012 [cited by applicant]
US 20130011210A1 · Toner et al. · 2013 [cited by applicant]
US 20130171685A1 · Schutze et al. · 2013 [cited by applicant]
US 20130190202A1 · Southern · 2013 [cited by applicant]
US 20130314526A1 · Yasuda et al. · 2013 [cited by applicant]
US 20140074008A1 · Fontanazzi et al. · 2014 [cited by applicant]
US 20140170735A1 · Holmes · 2014 [cited by applicant]
US 20140190888A1 · van Rijn · 2014 [cited by applicant]
US 20140248621A1 · Collins et al. · 2014 [cited by applicant]
US 20140376816A1 · Lagae et al. · 2014 [cited by applicant]
US 20150118728A1 · Rahman · 2015 [cited by applicant]
US 20150132766A1 · Yasuda · 2015 [cited by applicant]
US 20150238963A1 · Han et al. · 2015 [cited by applicant]
US 20160032350A1 · Hou et al. · 2016 [cited by applicant]
US 20160084814A1 · Olson et al. · 2016 [cited by applicant]
US 20160106353A1 · Schuetz et al. · 2016 [cited by applicant]
US 20160146823A1 · Chiu · 2016 [cited by applicant]
US 20160231274A1 · Tirapu Azpiroz et al. · 2016 [cited by applicant]
US 20160340636A1 · Tabata · 2016 [cited by applicant]
US 20160349232A1 · Shults et al. · 2016 [cited by applicant]
US 20170003267A1 · Meyer et al. · 2017 [cited by applicant]
US 20170080142A1 · Biran · 2017 [cited by applicant]
US 20170122861A1 · Lin · 2017 [cited by applicant]
US 20170212033A1 · Ozaki · 2017 [cited by applicant]
US 20170248508A1 · Ward et al. · 2017 [cited by applicant]
US 20170327783A1 · Grummitt · 2017 [cited by applicant]
US 20170368373A1 · Sahadevan · 2017 [cited by applicant]
US 20180104691A1 · Merten et al. · 2018 [cited by applicant]
US 20180128723A1 · Ryu et al. · 2018 [cited by applicant]
US 20180154361A1 · Foster et al. · 2018 [cited by applicant]
US 20180297085A1 · Deshpande et al. · 2018 [cited by applicant]
US 20180313816A1 · Fiering et al. · 2018 [cited by applicant]
US 20180321128A1 · Harriman · 2018 [cited by applicant]
US 20180334670A1 · Bharadwaj et al. · 2018 [cited by applicant]
US 20190022652A1 · Xie · 2019 [cited by applicant]
US 20190151847A1 · Bhagat · 2019 [cited by applicant]
US 20190195774A1 · El-Zehiry · 2019 [cited by applicant]
US 20190300928A1 · Krishnamurthy et al. · 2019 [cited by applicant]
US 20190332054A1 · Hong · 2019 [cited by applicant]
US 20190360915A1 · Foster · 2019 [cited by applicant]
US 20190369557A1 · Lee et al. · 2019 [cited by applicant]
US 20200206740A1 · Chiu et al. · 2020 [cited by applicant]
US 20200222905A1 · Hill et al. · 2020 [cited by applicant]
US 20200376488A1 · Wu et al. · 2020 [cited by applicant]
US 20210172950A1 · Toner et al. · 2021 [cited by applicant]
US 20210196767A1 · Minami et al. · 2021 [cited by applicant]
US 20210237064A1 · Parthasarathy · 2021 [cited by applicant]
US 20210237065A1 · Parthasarathy · 2021 [cited by applicant]
US 20210237066A1 · Parthasarathy · 2021 [cited by applicant]
US 20210237067A1 · Parthasarathy · 2021 [cited by applicant]
US 20210237068A1 · Parthasarathy · 2021 [cited by applicant]
US 20210237069A1 · Parthasarathy · 2021 [cited by applicant]
US 20210237070A1 · Parthasarathy · 2021 [cited by applicant]
US 20210237071A1 · Parthasarathy · 2021 [cited by applicant]
US 20210237072A1 · Parthasarathy · 2021 [cited by applicant]
US 20210237073A1 · Parthasarathy · 2021 [cited by applicant]
US 20210237074A1 · Parthasarathy · 2021 [cited by applicant]
US 20210237075A1 · Parthasarathy · 2021 [cited by applicant]
US 20210237076A1 · Parthasarathy · 2021 [cited by applicant]
US 20210252512A1 · Parthasarathy · 2021 [cited by applicant]
US 20210252513A1 · Parthasarathy · 2021 [cited by applicant]
US 20210346584A1 · Lee et al. · 2021 [cited by applicant]
US 20220088041A1 · Londesbrough et al. · 2022 [cited by applicant]
US 20220409584A1 · Bilal et al. · 2022 [cited by applicant]
US 20230033651A1 · Toner et al. · 2023 [cited by applicant]
CN 101629909B · 2012 [cited by applicant]
EP 1281951A1 · 2003 [cited by applicant]
EP 1190229B1 · 2011 [cited by applicant]
EP 2902108A1 · 2015 [cited by applicant]
WO WO1999061888A2 · 1999 [cited by applicant]
WO WO1999061888A3 · 1999 [cited by applicant]
WO 2009051734A1 · 2009 [cited by applicant]
WO WO2013085797A1 · 2013 [cited by applicant]
WO WO2017034517A1 · 2017 [cited by applicant]
WO WO2018035262A1 · 2017 [cited by applicant]
WO 2017189899A1 · 2017 [cited by applicant]
WO 2018020285A2 · 2018 [cited by applicant]
WO WO2018237239A1 · 2018 [cited by applicant]
WO 2019035952A1 · 2019 [cited by applicant]
WO WO2019040599A1 · 2019 [cited by applicant]
WO WO2019189408A1 · 2019 [cited by applicant]
WO WO2019195934A1 · 2019 [cited by applicant]
WO WO2019204333A1 · 2019 [cited by applicant]
WO WO2019204854A1 · 2019 [cited by applicant]
Sharma et al. “Circulating tumor cell isolation, culture, and downstream molecular analysis” (2018), Biotech Adv, vol. 36: 1063-1078. (Year: 2018). [cited by examiner]
Wormald et al. “On measuring 3D flow within inkjet droplet streams using a digital holographic microscope”(2010) J Modern Optics, vol. 57, No. 9: 700-708. (Year: 2010) [cited by examiner]
Gambro BCT, “COBE® Spectra Aphoresis System Essentials Guide”, Mar. 2005. [cited by applicant]
PCT International Search Report and Written Opinion for PCT Application PCT/US2021/015945; Apr. 21, 2021. [cited by applicant]
https://bmccancer.biomedcentral.com/track/pdf/10.1186/1471-2407-13-283.pdf; “Detection of Cancer Before Distant Metastasis” Article; Leon WMM Terstappen et. al.; BMC Cancer; Published Jun. 13, 2013. [cited by applicant]
https://www.nature.com/articles/s41408-020-0320-7.pdf; ““Direct to Drug” Screening as a Precision Medicine Tool in Multiple Myeloma” Article; Cecilia Bonolo de Campos et. al.; Blood Cancer Journal; Published May 11, 202… [cited by applicant]
https://www.mdpi.com/1422-0067/21/13/4813/pdf; “A Pilot Study of the Predictive Potential of Chemosensitivity and Gene Expression Assays Using Circulating Tumour Cells from Patients with Recurrent Ovarian Cancer” Articl… [cited by applicant]
https://www.mdpi.com/2072-6694/12/3/743/pdf; “Gauging the Impact of Cancer Treatment Modalities on Circulating Tumor Cells (CTCs)” Article; Michele I. Vitolo et. al.; Cancers Journal; Mar. 21, 2020. [cited by applicant]
https://www.pnas.org/content/pnas/117/29/16839.full.pdf; “Ultrahigh-Throughput Magnetic Sorting of Large Blood Volumes for Epitope-Agnostic Isolation of Circulating Tumor Cells” Article; Daniel A. Haber et. al.; PNAS; M… [cited by applicant]
https://wjso.biomedcentral.com/track/pdf/10.1186/1477-7819-11-159.pdf; “Extracorporeal Tumor Cell Filtration during Extended Liver Surgery: First Clinical use of Leukocyte Depletion Filters—a Case Series” Article; Nils … [cited by applicant]
https://clincancerres.aacrjournals.org/content/clincanres/24/22/5635.full-text.pdf; “Single-Cell Analyses of Prostate Cancer Liquid Biopsies Acquired by Apheresis” Article; Johann S. de Bono et. al.; AACR Publications; … [cited by applicant]
https://www.nature.com/articles/s41467-019-09439-9.pdf; “A Temporary Indwelling Intravascular Aphaeretic System for In Vivo Enrichment of Circulating Tumor Cells” Article; Sunitha Nagrath et. al.; Nature Communications;… [cited by applicant]
https://academic.oup.com/noa/article-pdf/2/1/vdaa052/33236713/vdaa052.pdf; “Evaluation of Neurapheresis Therapy In Vitro: a Novel Approach for the Treatment of Leptomeningeal Metastases” Article; Shivanand P. Lad et. al… [cited by applicant]
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4486079/pdf/nihms-702225.pdf; “The CTC-Chip: An Exciting New Tool to Detect Circulating Tumor Cells in Lung Cancer Patients” Article; Sunitha Nagrath, PhD et. al.; J Thorac O… [cited by applicant]
https://aip.scitation.org/doi/pdf/10.1063/1.5120501; “Label-Free Microfluidic Sorting of Microparticles” Article; Ian Papautsky et. al.; APL Bioengineering; Dec. 11, 2019. [cited by applicant]
https://onlinelibrary.wiley.com/doi/epdf/10.1002/cyto.a.23100; “Quantitative Phase Microscopy Spatial Signatures of Cancer Cells” Article; Darina Roitshtain et. al.; Submitted to Cytometry Part A; Wiley Online Library; … [cited by applicant]
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6261517/pdf/nihms982306.pdf; “An Intravascular Magnetic Wire for the High-Throughput Retrieval of Circulating Tumour Cells In Vivo” Article; Sanjiv S. Gambhir et. al.; Nat Bi… [cited by applicant]
Extended European Search Report for European Patent Application No. 21748010.2, mailed Jan. 30, 2024. [cited by applicant]
U.S. Appl. No. 17/162,450 2021/0237064, filed Jan. 29, 2021 Aug. 5, 2021, Jayant Parthasarathy, Biological Fluid Filtration System. [cited by applicant]
U.S. Appl. No. 17/205,338 2021/0237066, filed Mar. 18, 2021 Aug. 5, 2021, Jayant Parthasarathy, Biological Fluid Filtration System. [cited by applicant]
U.S. Appl. No. 17/205,393 2021/0237067, filed Mar. 18, 2021 Aug. 5, 2021, Jayant Parthasarathy, Biological Fluid Filtration System. [cited by applicant]
U.S. Appl. No. 17/205,508 2021/0237068, filed Mar. 18, 2021 Aug. 5, 2021, Jayant Parthasarathy, Biological Fluid Filtration System. [cited by applicant]
U.S. Appl. No. 17/205,595 2021/0237069, filed Mar. 18, 2021 Aug. 5, 2021, Jayant Parthasarathy, Biological Fluid Filtration System. [cited by applicant]
U.S. Appl. No. 17/205,171 2021/0237065, filed Mar. 18, 2021 Aug. 5, 2021, Jayant Parthasarathy, Biological Fluid Filtration System. [cited by applicant]
U.S. Appl. No. 17/205,769 2021/0237070, filed Mar. 18, 2021 Aug. 5, 2021, Jayant Parthasarathy, Biological Fluid Filtration System. [cited by applicant]
U.S. Appl. No. 17/206,405 2021/0237073, filed Mar. 19, 2021 Aug. 5, 2021, Jayant Parthasarathy, Biological Fluid Filtration System. [cited by applicant]
U.S. Appl. No. 17/206,231 2021/0237071, filed Mar. 19, 2021 Aug. 5, 2021, Jayant Parthasarathy, Biological Fluid Filtration System. [cited by applicant]
U.S. Appl. No. 17/206,271 2021/0237072, filed Mar. 19, 2021 Aug. 5, 2021, Jayant Parthasarathy, Biological Fluid Filtration System. [cited by applicant]
U.S. Appl. No. 17/211,373 2021/0237076, filed Mar. 24, 2021 Aug. 5, 2021, Jayant Parthasarathy, Biological Fluid Filtration System. [cited by applicant]
U.S. Appl. No. 17/211,277 2021/0237075, filed Mar. 24, 2021 Aug. 5, 2021, Jayant Parthasarathy, Biological Fluid Filtration System. [cited by applicant]
U.S. Appl. No. 17/313,421 2021/0252513, filed May 6, 2021 Aug. 5, 2021 Jayant Parthasarathy, Biological Fluid Filtration System. [cited by applicant]
U.S. Appl. No. 17/313,369 2021/0252512, filed May 6, 2021 Aug. 19, 2021 Jayant Parthasarathy, Biological Fluid Filtration System. [cited by applicant]